Drug response profiling can predict response to ponatinib in a patient with t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia

@inproceedings{Collette2015DrugRP,
  title={Drug response profiling can predict response to ponatinib in a patient with t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia},
  author={Yves Collette and Thomas Prebet and A Goubard and Jos{\'e} Ad{\'e}la{\"i}de and Rosetta Castellano and Nadine Carbuccia and Sophie Garnier and Arnaud Guille and Christine Arnoulet and A Charbonier and M J Mozziconacci and David J. Birnbaum and M Chaffanet and Norbert Vey},
  booktitle={Blood cancer journal},
  year={2015}
}
Tyrosine kinase inhibitor (TKI)-based targeted therapy has significantly modified the outcome for patients with chronic myeloid leukemia (CML) in chronic phase. However, resistance remains a major concern in blastic phase of CML and in Philadelphia chromosome positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL). Secondand third-generation TKIs have been developed to overcome resistance to first generation drugs, but selecting the appropriate drug has become a challenge. Various tests are… CONTINUE READING